Telix Pharmaceuticals has announced FDA acceptance of its resubmitted NDA for TLX101-Px (Pixclara®), a PET imaging agent for glioma, setting a PDUFA goal date of September 11, 2026. The agent addresses a significant unmet need in distinguishing recurrent glioma from treatment effects.
- FDA accepts resubmitted NDA for TLX101-Px with September 2026 PDUFA date
- TLX101-Px holds Fast Track and Orphan Drug designations for glioma imaging
- Agent targets LAT1 and LAT2 transporters, aiding glioma characterisation
- NDA acceptance marks key regulatory milestone but FY 2026 guidance excludes revenue
- TLX101-Px linked to Telix’s LAT1-targeting glioblastoma therapy under clinical trial
FDA Acceptance of TLX101-Px NDA
Telix Pharmaceuticals Limited (ASX:TLX, NASDAQ: TLX) has announced that the United States Food and Drug Administration (FDA) has accepted the company’s resubmitted New Drug Application (NDA) for TLX101-Px (Pixclara®), a positron emission tomography (PET) imaging agent designed for glioma characterisation. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 11, 2026, for the review outcome. This acceptance follows the NDA resubmission on March 13, 2026, which included additional data addressing prior regulatory concerns.
The NDA acceptance represents a significant regulatory milestone for Telix, advancing the potential commercialisation of a novel imaging agent aimed at improving the differentiation of recurrent or progressive glioma from treatment-related changes in both adult and paediatric patients.
Clinical and Regulatory Context for TLX101-Px
TLX101-Px, also known by its brand name Pixclara® pending final regulatory approval, has been granted both Fast Track and Orphan Drug designations by the FDA. These designations reflect the agent’s potential to address a critical unmet medical need in neuro-oncology, particularly in imaging gliomas, which are the most common malignant brain tumours. The agent targets L-type amino acid transporters 1 and 2 (LAT1 and LAT2), which are overexpressed in glioma cells, enabling improved imaging specificity.
International clinical guidelines, including those from the National Comprehensive Cancer Network (NCCN) and European neuro-oncology associations, already broadly recommend the use of 18F-Floretyrosine (F-FET) PET imaging for glioma characterisation. TLX101-Px utilises this tracer, positioning it as a potentially important diagnostic tool in the United States pending approval.
Expert Perspectives and Clinical Significance
Leading neuro-oncology experts have emphasised the importance of improved imaging modalities for glioma management. Dr Thomas Hope from the University of California, San Francisco, noted the critical unmet need in imaging residual glioma post-treatment and highlighted ongoing collaboration with Telix to facilitate patient access to FET-PET imaging in the US. Similarly, Dr Patrick Wen of Mass General Brigham Cancer Institute described the FDA’s acceptance of the NDA as a meaningful step toward broader clinical access, given the challenges in distinguishing tumour progression from treatment effects.
Link to Telix’s Therapeutic Pipeline
TLX101-Px is also being developed as a companion diagnostic for Telix’s LAT1-targeting therapy candidate TLX101-Tx (iodofalan 131I), which is currently under investigation in the pivotal IPAX-BrIGHT trial for recurrent glioblastoma. This linkage between diagnostic and therapeutic candidates could provide a more integrated approach to glioma management if both products receive regulatory approval.
Despite the regulatory progress, Telix’s financial guidance for fiscal year 2026 does not include any revenue contribution from TLX101-Px, reflecting the current stage of regulatory review and market entry planning.
Recent Company Developments and Outlook
This announcement follows Telix’s recent report of an 11% increase in Q1 2026 revenue to US$230 million and progress in multiple clinical trials, including its prostate cancer therapy TLX591-Tx. The company reaffirmed its full-year revenue guidance and continues to advance regulatory submissions for its imaging agents, including TLX101-Px, as detailed in its recent quarterly update.
Investors and observers will be watching the FDA’s review process closely, with the September PDUFA date marking a key event for Telix’s pipeline and potential market expansion in neuro-oncology. The company’s ongoing clinical and regulatory activities underscore its focus on radiopharmaceuticals addressing unmet needs in oncology and rare diseases.
For further details on Telix’s recent financial performance and clinical trial progress, see the company’s Q1 2026 revenue growth and prostate cancer therapy updates.
Bottom Line?
The FDA’s acceptance of the TLX101-Px NDA advances Telix’s neuro-oncology pipeline, but approval and commercial impact remain contingent on regulatory review and market uptake.
Questions in the middle?
- How will the FDA’s review address the additional data submitted with the NDA resubmission?
- What is the potential timeline and strategy for commercial launch if TLX101-Px receives approval?
- How might TLX101-Px’s approval influence the development and adoption of Telix’s LAT1-targeting therapy TLX101-Tx?